This study is being conducted to compare the efficacy of ABT-874 versus Methotrexate in subjects with moderate to severe plaque psoriasis.
This study is only being conducted in the EU and Canada
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
317
200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection
5.0 to 25 mg weekly
Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 24
Time frame: Week 24
The proportion of subjects who achieve a PGA score of 0 or 1 at Week 24
Time frame: Week 24
Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 52
Time frame: Week 52
The proportion of subjects who achieve a PGA score of 0 or 1 at Week 52
Time frame: Week 52
Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 24
Time frame: Week 24
Changes from Baseline in the DLQI total score at Week 24
Time frame: Week 24
Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 52
Time frame: Week 52
Changes from Baseline in the DLQI total score at Week 52
Time frame: Week 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site Reference ID/Investigator# 9904
Graz, Austria
Site Reference ID/Investigator# 11001
Vienna, Austria
Site Reference ID/Investigator# 12763
Vienna, Austria
Site Reference ID/Investigator# 8022
Brussels, Belgium
Site Reference ID/Investigator# 13104
Barrie, Canada
Site Reference ID/Investigator# 13161
Halifax, Canada
Site Reference ID/Investigator# 11864
Hamilton, Canada
Site Reference ID/Investigator# 13223
Québec, Canada
Site Reference ID/Investigator# 13221
Waterloo, Canada
Site Reference ID/Investigator# 11381
Aarhus, Denmark
...and 33 more locations